CASI CASI Pharmaceuticals Inc.: Net earnings per one share for the last twelve months

The operating cash flow of CASI Pharmaceuticals (CASI) is supported by the sale of approved oncology drugs in China, as confirmed by the EPS YoY TTM dynamics, where the metric level stands at -42.10. Financial stability is based on the commercialization of licenses and the expansion of the product pipeline. Business development relies on a cross-cultural synthesis of US and Asian science, attracting specialists through large-scale investments in innovative research.

CASI Pharmaceuticals Inc. (CASI): Net earnings per share (EPS TTM) from 02/11/2024 to 03/14/2026

CASI Pharmaceuticals - analytical breakdowns and key metrics (CASI)

- share price and expert price forecast:

Price Chart CASI Pharmaceuticals, Inc.|CASI - Price Target Chart

- company stock capitalization data:

Market Value CASI Pharmaceuticals, Inc|CASI - Total Company Value

- company book value details:

Net Asset Value per Share CASI Pharmaceuticals|CASI - Book Capitalization|Capitalization to Book Value Ratio casipharmaceuticals.com|CASI - Company Total Assets

- debt and liquidity data:

- net income and valuation ratios data:

CASI - Company Net Income|Forward Earnings CASI Pharmaceuticals|CASI - P/E Multiple|Future Price to Earnings Multiple casipharmaceuticals.com|CASI - PEG Multiple|EV/EBITDA Multiple CASI Pharmaceuticals, Inc|CASI - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year CASI Pharmaceuticals|CASI - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months casipharmaceuticals.com|CASI - Earnings growth in current year|Earnings growth forecast for next year CASI Pharmaceuticals

- sales and revenue indicators:

CASI - Revenue and Sales Volume|Company Future Sales Volume casipharmaceuticals.com|CASI - P/S Multiple|Market Cap to Future Revenue Ratio CASI Pharmaceuticals

Initial company analysis:CASI (CASI Pharmaceuticals Inc.)

Manufactured product of CASI Pharmaceuticals, Inc

This indicator measures the annual growth rate of net income per share over a rolling 12-month period, identifying deviations in operational efficiency from historical trends. By analyzing the 12-month EPS YoY history, an investor can assess how the commercialization of oncology drugs in the Chinese market converts into real shareholder returns for CASI Pharmaceuticals (CASI), separating systemic growth from one-time accounting adjustments.

Competitor analysis for CASI Pharmaceuticals